Although business headlines still tout earnings numbers, many investors have moved past net earnings as a measure of a company’s economic output. That’s because earnings are very often less trustworthy than cash flow, since earnings are more open to manipulation based on dubious judgment calls.
Earnings’ unreliability is one of the reasons Foolish investors often flip straight past the income statement to check the cash flow statement. In general, by taking a close look at the cash moving in and out of the business, you can better understand whether the last batch of earnings brought money into the company, or merely disguised a cash gusher with a pretty headline.
Calling all cash flows
When you are trying to buy the market’s best stocks, it’s worth checking up on your companies’ free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That’s what we do with this series. Today, we’re checking in on Foot Locker (NYSE: FL ) , whose recent revenue and earnings are plotted below.
Top 5 Building Product Companies To Own In Right Now: BG Medicine Inc.(BGMD)
BG Medicine, Inc., a life sciences company, engages in the discovery, development, and commercialization of diagnostic tests based on biomarkers in the United States. Its product pipeline includes BGM Galectin-3, a diagnostic test for heart failure that measures galectin-3 levels in blood plasma or serum; AMIPredict, a multivariate biomarker blood-based test for atherothrombotic cardiovascular disease; and LipidDx, a blood-based protein assay for the management of patients with lipid disorders. The company also offers TNF alpha blockers comprising Enbrel, Remicade and Humira, which are treatments indicated for autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn?s disease. It has strategic collaborations and initiatives with pharmaceutical companies and other healthcare organizations, including Abbott Laboratories; ACS Biomarker B.V.; Humana Inc.; Merck & Co., Inc.; and Laboratory Corporation of America. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.
- [By James E. Brumley]
What do BG Medicine, Inc. (NASDAQ:BGMD) and Pentair, Ltd. (NYSE:PNR) have in common? Most investors would say absolutely nothing. BGMD is a small cap medical diagnostics company, while PNR is a large cap industrial equipment manufacturer. Those are worlds that simply never collide. The directions each stock has been traveling in over the past few months have even been polar opposites.
Top 5 Building Product Companies To Own In Right Now: Novartis AG (NVS)
Novartis AG, incorporated on February 29, 1996, provides healthcare solutions. The Company is a multinational group of companies specializing in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. Its portfolio includes medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. The Company has five segments: Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals; vaccines and diagnostics, which include human vaccines and blood-testing diagnostics, and consumer health, which include over-the-counter medicines (OTC) and Animal Health. On April 8, 2011, the Company acquired the remaining non-controlling interest in Alcon, Inc. In December 2013, Alliance Pharma plc announced that its wholl y owned subsidiary, Alliance Pharmaceuticals Limited, acquired all the United Kingdom and Republic of Ireland (ROI) rights to Lypsyl from Novartis AG.
In April 2011, Novartis sells global rights to Elidel, a medicine to treat atopic dermatitis to Meda. In March 2011, Novartis completes acquisition of majority stake in Zhejiang Tianyuan vaccines company in China. In March 2011, the Company acquired Genoptix, Inc. In October 2011, Novartis discontinues development of AGO178 for depressive disorder. In December 2011, the Company discontinues development of PRT128 for acute coronary syndrome and chronic coronary heart disease, and SMC021 for osteoporosis and osteoarthritis. In April 2011, Alcon’s portfolio of generic ophthalmic medicines sold through its Falcon business unit primarily in the United States.
The Company’s Pharmaceuticals Division researches, develops, manufactures, distributes and sells patented pr escription medicines in the therapeutic areas, such as Oncol! ogy; Primary Care, consisting of Primary Care medicines and Established Medicines, and Specialty Care, consisting of Ophthalmology, Neuroscience, Integrated Hospital Care, and Critical Care medicines. The Pharmaceuticals Division is organized into global business franchises responsible for the commercialization of various products, as well as Novartis Oncology, a business unit responsible for the global development and commercialization of oncology products, and Novartis Molecular Diagnostics, a business responsible for the development and commercialization of diagnostic tests and services related to its pharmaceuticals portfolio and therapeutic areas.
The Company’s Oncology products include Afinitor/Votubia, Exjade, Sandostatin SC/Sandostatin LAR , Femara , Zometa, Tasigna and Gleevec/Glivec. Gleevec/Glivec, which is a signal transduction inhibitor approved to treat patients with certain forms of chronic myeloid leukemia (CML) and gastrointestinal stromal tu mors (GIST). Tasigna is a signal transduction inhibitor of the tyrosine kinase activity of Bcr-Abl, KIT+ and the PDGF-receptor. Zometa is a treatment to reduce or delay skeletal-related events (SREs), including pathologic fracture, spinal cord compression, and/or requirement of radiation therapy or surgery to bone, in patients with bone metastases (cancer that has spread to the bones) from solid tumors and multiple myeloma. Femara is a once-daily oral aromatase inhibitor for the treatment of early stage or advanced breast cancer in postmenopausal women. Sandostatin SC/Sandostatin LAR is indicated for the treatment of patients with acromegaly, a chronic disease caused by over-secretion of pituitary growth hormone in adults. Sandostatin is also indicated for the treatment of patients with certain symptoms associated with carcinoid tumors and other types of gastrointestinal and pancreatic neuroendocrine tumors. Exjade is an oral iron chelator approved for the treatment of chron ic iron overload due to blood transfusions in patients over ! two years! of age who have a range of underlying anemias. Patients with congenital and acquired chronic anemia, such as thalassemia, sickle cell disease and myelodysplastic syndromes, require transfusions, which puts them at risk of iron overload. Afinitor/Votubia is an oral inhibitor of the mTOR pathway.
The Company’s Primary Care products include Arcapta Neohaler/Onbrez Breezhaler, Diovan, Exforge, Tekturna/Rasilez, Galvus, Reclast/Aclasta, Voltaren/Cataflam, Ritalin, Ritalin LA, Focalin and Focalin XR. Its Specialty Care products include Lucentis, Gilenya, Exelon, Extavia and Comtan, and Stalevo. Its Integrated Hospital Care include Zortress/Certican, Ilaris, Neoral and Myfortic.The Company’s Critical Care products include Xolair and Tobi Podhaler. As of December 31, 2011, the products under development includes ACZ885, which is being investigated for the secondary prevention of cardiovascular events and for the treatment of Diabetes Mellitus; AEB071 (sotrastaurin) is a low molecular weight, selective inhibitor of protein kinase-C (PKC); AFQ056 (mavoglurant) is a metabotropic glutamate receptor 5 (mGluR5) antagonist in Phase II development for the treatment of Parkinson’s disease levodopa-induced dyskinesia; AIN457 (secukinumab) is a human monoclonal antibody neutralizing interleukin-17A, a key pro-inflammatory cytokine expressed by TH17 cells and other types of white blood cells; BAF312 is an oral, second-generation sphingosine 1-phosphate receptor modulator in Phase II development for relapsing-remitting multiple sclerosis; DEB025 (alisporivir) is a cyclophilin inhibitor for the treatment of Hepatitis C virus infection (HCV); Gileny a line treatment for relapsing forms of MS; Exjade (deferasirox) is an oral iron chelator in development for use in patients with non-transfusion-dependent thalassemia (NTDT); INC424 (ruxolitinib) is an investigational Janus kinase (JAK) inhibitor, and Zortress/Certican (everolimus) is an mTOR inhibitor with immune/non-immune cell proliferation inhibition being d! eveloped ! for prevention of solid organ transplant rejection.
The Company’s Alcon Division discovers, develops, manufactures, distributes and sells eye care products. Alcon is engaged in eye care with product offerings in Surgical, Ophthalmic Pharmaceuticals and Vision Care. In Surgical, Alcon develops, manufactures, distributes and sells ophthalmic surgical equipment, instruments, disposable products and intraocular lenses. In Pharmaceutical, Alcon discovers, develops, manufactures, distributes and sells medicines to treat chronic and acute diseases of the eye, as well as over-the-counter medicines for the eye. In Vision Care, Alcon develops, manufactures, distributes and sells contact lenses and lens care products.
Alcon’s Surgical portfolio includes the Infiniti vision system for cataract procedures, the Constellation vision system for retinal operations, and the AcrySof family of intraocular lenses (IOLs), including the AcryS of IQ, AcrySof IQ ReSTOR, AcrySof IQ Toric and AcrySof IQ ReSTOR Toric IOLs. During the year ended December 31, 2011, its Alcon Division launched the LenSx femtosecond laser, a technology in cataract surgery, which increases the precision and reproductibility for corneal incisions, capsulorhexis and lens fragmentation steps of the procedure. In addition, Alcon provides advanced viscoelastics, surgical solutions, surgical packs and other disposable products for cataract and vitreoretinal surgery.
Alcon Division’s Ophthalmic Pharmaceuticals business combines Alcon’s range of pharmaceuticals with selected ophthalmic products (excluding Lucentis) previously marketed by the Novartis Pharmaceuticals Division. The products treat chronic and acute diseases of the eye including glaucoma and allergies, as well as anti-infective/anti-inflammatory and dry eye treatments. our Alcon Division’s Ophthalmic Pharmaceuticals portfolio include Travatan Z solution and DuoTrav soluti on for the treatment of elevated intraocular pressure associ! ated with! glaucoma; Vigamox solution for bacterial conjunctivitis; Pataday solution for ocular itching associated with allergic conjunctivitis; and Nevanac suspension for eye inflammation following cataract surgery. Alcon launched a number of products during 2011, including Dailies Total 1 lenses, Opti-Free EverMoist Multi Purpose Disinfecting Solution, LenSx laser, AcrySof IQ ReSTOR Toric lens, AcrySof IQ Toric T6-T9 lens, Travatan BAK-free solution, DuoTrav BAK-free solution, Moxeza solution and Systane Balance eye drops.
The Company’s Sandoz Division is a global generic pharmaceuticals company that develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical and biotechnological active substances, which are not protected by valid and enforceable third-party patents. The Sandoz Division has activities in Retail Generics, Anti-Infectives, and Biopharmaceuticals and Oncology Injectables. In Retail Generics , Sandoz develops, manufactures and markets active ingredients and finished dosage forms of pharmaceuticals, as well as supplying active ingredients to third parties. In Anti-Infectives, Sandoz develops and manufactures active pharmaceutical ingredients and intermediates, mainly antibiotics, for internal use by retail generics and for sale to third-party customers. In Biopharmaceuticals, Sandoz develops, manufactures and markets protein- or other biotechnology-based products (biosimilars or follow-on biologics) and sells biotech manufacturing services to other companies.
In Oncology Injectables, Sandoz develops, manufactures and markets primarily cytotoxic products for the hospital market. During 2011, the Company launched generic docetaxel (Taxotere), higher-strength generic amlodipine-benazepril (Lotrel), generic meropenem (Merem) injection, and the formation of a women’s health portfolio with generic Seasonale, Nordette, Yaz and Yasmin. The product launched in various European countries included generic docetaxel, ge! neric ana! strazole (Arimidex), and valsartan/covalsartan (an early entry generic version of Novartis Pharmaceuticals’ Diovan/Co-Diovan).
Vaccines and Diagnostics Division
The Company’s Vaccines and Diagnostics Division researches, develops, manufactures, distributes and sells preventive vaccines and diagnostic tools. Novartis Vaccines is a global developer and manufacturer of human vaccines. Novartis Diagnostics is a blood testing and molecular diagnostics business dedicated to preventing the spread of infectious diseases through blood-screening tools that protect the world’s blood supply. Novartis Vaccines’ products include influenza, meningococcal, pediatric, adult and travel vaccines.
The Company’s influenza vaccines include Agrippal, Fluad, Fluvirin and Optaflu. Its Meningococcal Vaccines includes Menjugate and Menveo. Its travel vaccines include Encepur Children, Encepur Adults, Ixiaro and Rabipur/Rabavert. Its Pediatric Vaccines includ e Polioral and Quinvaxem.
Consumer Health consists of two Divisions: OTC (over-the-counter medicines) and Animal Health. Each has its own research, development, manufacturing, distribution and selling capabilities. OTC offers readily available consumer medicine. Animal Health provides veterinary products for farm and companion animals.
OTC (over-the-counter medicines) offers products for the treatment and prevention of common medical conditions and ailments. OTC business focuses on a group of global brands in product categories that include treatments for cough/cold/respiratory (Triaminic, Otrivin, TheraFlu/NeoCitran), pain relief (Excedrin, Voltaren), digestive health (Benefiber, Prevacid24HR, Pantoloc Control), dermatology (Lamisil, Fenistil), and smoking cessation (Habitrol/Nicotinell).
Animal Health offers products and services focusing on both companion and farm animals (including cultivated fish). Key products for c ompanion animals include Atopica (atopic dermatitis manageme! nt), Dera! maxx and Onsior (pain relief), Fortekor (heart failure in dogs, chronic renal insufficiency in cats), and Sentinel/Milbemax/Interceptor (intestinal parasite control and heartworm prevention), while farm animal products include the therapeutic anti-infective Denagard, an antimicrobial used to treat and control bacteria in swine, CLiK, an insect growth regulator used to control blowfly strike in sheep, cattle vaccines used to prevent respiratory and reproductive diseases in beef and dairy cattle, and Zolvix, a sheep drench representing the new sheep anthelmintic class. Aquaculture products include vaccines and treatments mainly used in salmon farming.
- [By WWW.DAILYFINANCE.COM]
Andrew Yates, AFP/Getty Images LONDON — The board of AstraZeneca on Monday rejected the improved $119 billion takeover offer from U.S. drugmaker Pfizer, a decision that caused a sharp slide in the U.K. company’s share price as many investors think it effectively brings an end to the protracted and increasingly bitter takeover saga. The board said in a statement that it “reiterates its confidence in AstraZeneca’s ability to deliver on its prospects as an independent, science led business.” Pfizer (PFE), which is the world’s second-biggest drugmaker by revenue, has been courting No. 8 AstraZeneca (AZN) since January, arguing their businesses are complementary. On Sunday, it raised its stock-and-cash offer by 15 percent to $118.8 billion, or 70.73 billion pounds. That would be the richest acquisition ever among drugmakers and the third-biggest in any industry, according to figures from research firm Dealogic. AstraZeneca didn’t take long to reject the new offer, its board arguing Pfizer is making “an opportunistic attempt to acquire a transformed AstraZeneca, without reflecting the value of its exciting pipeline” of experimental drugs. Because Pfizer said it won’t raise its offer again or launch a hostile takeover bid over the heads of AstraZeneca’s board, the prospect of a deal looks increasingly remote unless AstraZeneca shareholders urge a change of mind. Pfizer has said it hopes AstraZeneca’s shareholders will push for a deal. “This has been going on for quite some time and we have been in very deep engagement over the whole of the weekend,” AstraZeneca Chairman Leif Johansson told the BBC. “If Pfizer now says this is the final offer I have to believe what they say.” Shareholders in AstraZeneca seemed to think a deal is now unlikely, with the company’s share price slumping 11 percent to 43.15 pounds. Johansson said his management team had told Pfizer over the weekend that it would need to see a 10 percent improvement over the 53.50 pounds-per-shar
- [By Brian Orelli]
Shares of the biotech have been on a bit of a roller coaster over the last year as investors went from having high hopes for Ariad Pharmaceutical’s leukemia drug Iclusig to seeing the drug getting pulled from the market because the drug is linked to blood clots. After returning to the market, Ariad’s shares have more than doubled off their lows, but are still well off of where they were when investors thought Iclusig could compete with Novartis’ (NYSE: NVS ) Gleevec and Bristol-Myers Squibb’s (NYSE: BMY ) Sprycel as first-line treatments.
- [By Arrow Analysis]
Acquiring AstraZeneca has a lot of potential benefits for Pfizer. For one, this merger would make Pfizer the largest pharmaceutical company in terms of revenue gain. With the announcement of the recent three way deal between GlaxoSmithKline (GSK), Novartis (NVS) and Eli Lilly (LLY), Pfizer Inc desperately needs something to keep investors interested – and for the right reasons.
Top 5 Building Product Companies To Own In Right Now: US Ecology Inc.(ECOL)
US Ecology, Inc., through its subsidiaries, provides waste treatment, disposal, recycling, and transportation services to commercial and government entities in the United States. The company offers treatment and disposal services for radioactive, hazardous, polychlorinated biphenyl, and non-hazardous industrial wastes. Its customers include oil refineries, chemical production facilities, manufacturers, electric utilities, steel mills, biotechnology companies, military installations, waste brokers/aggregators, and medical and academic institutions. The company was formerly known as American Ecology Corporation and changed its name to US Ecology, Inc. in February 2010. US Ecology, Inc. was founded in 1952 and is headquartered in Boise, Idaho.
- [By Damian Illia] ides waste management and recycling services to manufacturing, industrial and energy-related sectors. The company’s five waste sites treat hazardous and non-hazardous industrial waste, as well as radioactive and PCB waste. In addition, the company´s Robstown treatment plant in Texas counts with a thermal desorption unit that treats refinery sludge.
In the following sections I will show you that we are dealing with a very profitable growth stock, that has an above average ROE rate of 13.89%, and operates with a net margin of 15.99%.
Holding a Strong Position in the Market
ECOL has two revenue streams. Business contracts to treat customers’ periodic disposal needs on the one hand, and event-driven services that apply to special projects or cleanup work on the other.
Furthermore, the company has a wide economic moat largely stemming from three factors: its efficient scale, its high switching costs and its intangible assets. Of the 20 commercial hazardous-waste landfills operational in the U.S., the majority are run by US Ecology and its main competitors Waste Management Inc. (WM), and Clean Harbors Inc. (CLH). With barriers to entry stemming from regulatory permits, and a limited market size, ECOL has managed to achieve an efficient scale in the market with five hazardous waste-sides. The company’s intangible assets consist of long-term regulatory permits, which enable US Ecology to posses a “gatekeeper privilege” regarding barriers to new entrants. In addition, customer switching costs are high, thus further adding to the firm’s ability to sustain growth in the long term.
Good Investments and New Management Should Ensure Profitable Growth
A range of new treatment services should also help ensure profitable growth for coming years. For example, the Texas facility which operates a new thermal desorption technology for oil refinery sludge since 2008 has been responsible for 10% of revenue and is expected to keep grow
- [By Damian Illia]
As we can see, the firm has a higher ROE than Amrep Corporation (AXR) but is well below the one registered by US Ecology Inc. (ECOL) and Cintas Corporation (CTAS).
- [By Lauren Pollock]
Among the stocks to watch in Monday’s session are US Ecology Inc.(ECOL), Akamai, and Dow Chemical Co.(DOW)
US Ecology again raised its earnings guidance for the year, pointing to strong volumes and accelerated project shipments, but warned its results for next year may take a hit as a result. The company, which provides waste- management and recycling services, also outlined plans to offer about $100 million in stock. Shares dropped 10% to $34.51 premarket.
- [By Seth Jayson]
US Ecology (Nasdaq: ECOL ) is expected to report Q1 earnings on April 25. Here’s what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict US Ecology’s revenues will increase 20.4% and EPS will grow 19.0%.
Top 5 Building Product Companies To Own In Right Now: MicroFinancial Incorporated(MFI)
Microfinancial Incorporated, through its subsidiaries, operates as a specialized commercial finance company that provides microticket equipment leasing and rental, and other financing services in the United States. The company provides financing alternatives, and leases and rents commercial equipment to start-up and established businesses for use in their daily operations. It leases water filtration systems, food service equipment, security equipment, point-of-sale cash registers, salon equipment, health care and fitness equipment, and automotive equipment. The company primarily sources its originations through a network of independent equipment vendors, sales organizations, and other dealer-based origination networks. Microfinancial Incorporated was founded in 1987 and is headquartered in Woburn, Massachusetts.
- [By Magic Diligence]
One stock that has been in the official Magic Formula (MFI) screen for the past month or so has piqued my interest: Kraft (KRFT).
The MFI screens, particularly the $50 million screen, are usually reserved for deep value stocks. Usually you find stocks in here suffering serious adverse business developments (LQDT, NSR, etc.), operate in out-of-favor industries (APOL, STRA, etc.), have volatile and difficult-to-predict future prospects (PDLI comes to mind), or are just simply cheap quantitatively (CSCO, COH, et.al.).
- [By Gerrit De Vynck]
Maple Leaf Foods Inc. (MFI), the Canadian producer of foods from hamburgers to frozen pasta, has drawn bids for its bread unit from Grupo Bimbo SAB, Flowers Foods Inc. (FLO) and several private-equity firms, three people with knowledge of the matter said.
- [By Eric Lam]
Alacer Gold Corp. and Iamgold Corp. rallied at least 5.9 percent as the metal traded at its highest in 11 weeks. Maple Leaf Foods Inc. (MFI) jumped 7.8 percent as it agreed to sell a unit for C$645 million ($614 million). Penn West Petroleum (PWT) Ltd. added 1.7 percent after cutting 25 percent of its workforce to reduce costs.
Top 5 Building Product Companies To Own In Right Now: Morgan Stanley(MS)
Morgan Stanley, a financial holding company, provides various financial products and services to corporations, governments, financial institutions, and individuals worldwide. It operates in three segments: Institutional Securities, Global Wealth Management Group, and Asset Management. The Institutional Securities segment offers financial advisory services on mergers and acquisitions, divestitures, joint ventures, corporate restructurings, recapitalizations, spin-offs, exchange offers, and leveraged buyouts and takeover defenses, as well as shareholder relations, capital raising, corporate lending, and investments. This segment also engages in sales, trading, financing, and market-making activities, including equity trading, commodities, and interest rates, credit, and currencies, as well as financing services, such as prime brokerage, consolidated clearance, settlement, custody, financing, and portfolio reporting services. The Global Wealth Management Group segment provide s brokerage and investment advisory services covering various investment alternatives comprising equities, options, futures, foreign currencies, precious metals, fixed income securities, mutual funds, structured products, alternative investments, unit investment trusts, managed futures, separately managed accounts, and mutual fund asset allocation programs; education savings programs, financial and wealth planning services, and annuity and insurance products; credit and other lending products; cash management services; retirement services; and trust and fiduciary services. The Asset Management segment offers products and services in equity, fixed income, and alternative investments, such as hedge funds, fund of funds, real estate, private equity, and infrastructure to institutional and retail clients through proprietary and third party distribution channels. This segment also involves in investment and merchant banking activities. The company was founded in 1935 and is head q uartered in New York.
- [By Gillian Tan]
Bank of America now trails Goldman in Dealogic’s ECM league tables by a mere $176 million, with market share of 11.2% compared to Goldman’s 11.4%. Citigroup Inc.(C) is ranked third with 10.9%, followed by J.P.Morgan and Morgan Stanley(MS) with share of 10.5% and 10.1% respectively.
- [By WWW.DAILYFINANCE.COM]
Jeff Chiu/AP So far, 2014 has been a high-scoring year for initial public stock offerings. The first quarter saw more IPO activity than any other initial quarter since 2000, with 64 companies listing on various U.S. exchanges raising a collective $10.6 billion. That’s more than double the number of IPOs that took place in the first quarter of 2013. This is directly related to the health of the overall stock market. Generally speaking, the better shares are performing, the higher the chance of an issuer being successful on IPO day. After all, who’s eager to buy anything when the market’s in the doldrums? Yet even in a good environment for IPOs, companies occasionally get the jitters and withdraw their listings. Sometimes this is due to the overall atmosphere on the market; sometimes it’s because of difficulties with the issuing company itself; sometimes it’s both. Whatever the reason(s), the notable examples below scampered away before they could become publicly traded entities. Square One of the top anticipated IPOs of 2014 was for this cutting-edge e-commerce company, which pioneered the use of smartphone and tablet payment card readers. Then there’s Square’s impeccable geek credentials, thanks in no small part to its founder-CEO Jack Dorsey, who was one of the guiding lights behind Twitter (TWTR). That, apparently, wasn’t enough to bring it to market. In late February, media reports had it that the company postponed its planned IPO indefinitely. It seems that it’s burning through cash very quickly and doesn’t have enough revenue to cover this. Instead of listing on an exchange, the firm is reportedly looking for a deep-pocketed suitor and has allegedly held discussions with Google (GOOG), Apple (AAPL) and eBay (EBAY), and possibly even one of its investors, Visa (V), regarding a potential buyout. Square denies it has been in acquisition talks. Trustwave Holdings Another nonstarter in the tech IPO space was Trustwave, which provides on-demand data secu